Time Medical India unveils next-generation MRI platforms at IRIA 2026
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Subscribe To Our Newsletter & Stay Updated